Piramal Pharma LimitedNSE: PPLPHARMA

Press Release Jan 29 2026

· Issued by Piramal Pharma Limited

Filed with NSE · · 28 pages · English

Summary by 6ix AI

The report indicates that revenue growth was impacted by inventory destocking and slower order inflows due to market uncertainties and regulatory delays. Despite these challenges, the company is seeing early signs of recovery in order inflows and has made significant investments to expand its facilities. The filing also discusses the acquisition of Kenalog, which is expected to enhance the company's product portfolio and profitability.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Piramal Pharma Limited on 6ix

In the deck

Earlier from Piramal Pharma

Later from Piramal Pharma

All Piramal Pharma news releases